Lymphocytic Choriomeningitis Virus Infection

Lymphocytic choriomeningitis virus (LCMV) is a zoonotic, enveloped, single-stranded RNA virus belonging to the family Arenaviridae, genus Mammarenavirus. It is a classic cause of aseptic meningitis, encephalitis, and congenital malformations in humans, but in its natural rodent hosts—particularly the house mouse (Mus musculus)—it establishes a persistent, often subclinical infection. In pet rodents, including fancy rats (Rattus norvegicus), mice (Mus musculus), and hamsters (Mesocricetus auratus), LCMV infection is typically asymptomatic or causes mild, non-specific signs, yet it poses a significant public health concern due to its transmissibility to humans. The virus is shed in urine, feces, saliva, and nasal secretions, and transmission occurs via inhalation of aerosolized particles, direct contact with contaminated fomites, or through bites. In immunocompetent adult rodents, infection is usually self-limiting, but in neonates or immunocompromised animals, it can lead to chronic viremia and persistent shedding. The disease is of particular importance in laboratory animal medicine and in the pet trade, where infected rodents may serve as silent reservoirs. Clinical disease in rodents is rare, but when present, it may manifest as weight loss, lethargy, neurological signs (tremors, seizures, paralysis), or reproductive failure. Diagnosis relies on serology (ELISA, IFA), RT-PCR, or virus isolation. Management focuses on prevention, biosecurity, and zoonotic risk mitigation. In human medicine, LCMV is a recognized cause of congenital hydrocephalus and chorioretinitis, and it has been associated with severe disease in organ transplant recipients. Therefore, exotic animal practitioners must be vigilant in recognizing and managing LCMV in pet rodents to protect both animal and human health.

The primary causative agent is Lymphocytic choriomeningitis virus (LCMV), a member of the family Arenaviridae, genus Mammarenavirus. It is an enveloped virus with a bisegmented negative-sense RNA genome. The large (L) segment encodes the RNA-dependent RNA polymerase and a zinc-binding protein, while the small (S) segment encodes the nucleoprotein and the glycoprotein precursor (GPC), which is cleaved into GP1 and GP2. The virus is pleomorphic, with a diameter of 50-300 nm, and exhibits a characteristic sandy appearance on electron microscopy due to host ribosomes incorporated into the virion. LCMV is closely related to other arenaviruses such as Lassa virus and Machupo virus, but it is the only arenavirus endemic in North America and Europe. The natural reservoir is the house mouse (Mus musculus), but other rodents, including hamsters, guinea pigs, and rats, can become infected. In persistently infected mice, the virus establishes a lifelong infection with high viral titers in blood and organs, and shedding occurs continuously. The virus is relatively stable in the environment, surviving for several hours on dry surfaces and longer in moist conditions. It is inactivated by heat (56°C for 30 minutes), ultraviolet light, and common disinfectants such as 10% bleach, 70% ethanol, and glutaraldehyde. The virus can be transmitted horizontally through direct contact, aerosolization, and fomites, and vertically from dam to offspring, leading to congenital infection. In pet rodents, infection is often acquired from wild mice or from contaminated bedding, feed, or water. The virus has a broad host range, and humans are accidental hosts. The pathogenesis is immune-mediated, with the host's cytotoxic T-cell response contributing to the development of choriomeningitis and other clinical signs. In rodents, the outcome of infection depends on the age and immune status of the host: neonatal infection leads to persistent infection and immune tolerance, while adult infection results in acute, self-limiting disease with viral clearance.

LCMV is distributed worldwide, with seroprevalence in wild house mice ranging from 5% to 20% in some regions. In pet rodents, the prevalence is generally low, but outbreaks have been reported in breeding facilities and pet stores. The virus is more common in mice than in rats or hamsters, but hamsters have been implicated in human infections, particularly in the 1970s when contaminated hamster colonies caused outbreaks of LCMV in humans in the United States and Germany. In pet rats, the prevalence is estimated to be less than 1%, but the risk increases with exposure to wild rodents. The disease is of particular concern in immunocompromised individuals, pregnant women, and organ transplant recipients, where it can cause severe or fatal disease. In rodents, the infection is often subclinical, and the virus can persist in the population through vertical transmission. Factors that increase the risk of infection include overcrowding, poor sanitation, introduction of new animals from unknown sources, and exposure to wild rodents. The virus is more common in laboratory animal facilities than in pet populations, but pet owners and veterinary staff are at risk of zoonotic transmission. The incubation period in rodents is typically 5-7 days, and viral shedding can occur for weeks to months. In humans, the incubation period is 1-2 weeks, and the disease can range from a mild flu-like illness to severe neurological disease. The epidemiology of LCMV in pet rodents is poorly characterized, but it is likely underdiagnosed due to the lack of clinical signs in most animals. Veterinarians should consider LCMV in the differential diagnosis of any rodent with neurological signs or reproductive failure, and they should implement appropriate biosecurity measures to prevent zoonotic transmission.

The pathophysiology of LCMV infection in rodents is complex and involves both direct viral cytopathology and immune-mediated mechanisms. After initial infection, the virus replicates in the respiratory epithelium and then spreads to regional lymph nodes, where it undergoes primary replication. Subsequently, viremia occurs, and the virus disseminates to multiple organs, including the spleen, liver, and brain. In adult immunocompetent mice, the infection is controlled by a robust cytotoxic T-lymphocyte (CTL) response, which clears the virus from most tissues within 2-3 weeks. However, the CTL response also contributes to the pathogenesis of the disease, particularly in the central nervous system (CNS). The classic manifestation of LCMV in mice is lymphocytic choriomeningitis, which occurs when the virus infects the meninges and ependymal cells. The CTL response to viral antigens in these tissues leads to inflammation, edema, and neuronal damage, resulting in the clinical signs of meningitis and encephalitis. In contrast, neonatal or congenitally infected mice develop immune tolerance to the virus, leading to persistent infection with high viral titers in the blood and tissues. These persistently infected mice are typically asymptomatic but shed the virus throughout their lives. The mechanism of immune tolerance involves the deletion of virus-specific CTLs in the thymus, leading to a lack of an effective immune response. In hamsters, the pathogenesis is similar, but the disease is often more severe, with hepatitis and neurological signs. In rats, LCMV infection is usually subclinical, but it can cause reproductive failure and growth retardation. The virus can also cross the placenta and infect the fetus, leading to congenital malformations, including hydrocephalus and chorioretinitis. In humans, the pathogenesis is similar to that in adult mice, with the CTL response causing the characteristic symptoms of aseptic meningitis and encephalitis. The virus can also infect the placenta and cause congenital infection, leading to severe fetal damage. Overall, the pathophysiology of LCMV is a balance between viral replication and the host's immune response, with the outcome depending on the age and immune status of the host.

Several intrinsic and extrinsic factors predispose rodents to LCMV infection and influence the severity of the disease. Intrinsic factors include species, age, and immune status. Mice are the natural reservoir and are more susceptible to persistent infection, while rats and hamsters are less commonly affected. Neonatal and young animals are more susceptible to persistent infection and severe disease due to the immaturity of their immune system. Immunocompromised animals, whether due to stress, concurrent disease, or immunosuppressive therapy, are at higher risk of developing clinical disease and shedding the virus. Extrinsic factors include husbandry and environmental conditions. Overcrowding, poor sanitation, and inadequate ventilation increase the risk of viral transmission. Exposure to wild rodents, either directly or through contaminated feed, bedding, or water, is a major risk factor. The introduction of new animals from unknown sources without proper quarantine can introduce the virus into a colony. Stressful conditions, such as transportation, weaning, or changes in environment, can exacerbate the disease and increase viral shedding. In pet rodents, the risk of infection is higher in animals obtained from pet stores or breeding facilities with poor biosecurity. Additionally, the use of immunosuppressive drugs, such as corticosteroids, can reactivate latent infections and increase the severity of the disease. The zoonotic risk is higher in pregnant women, immunocompromised individuals, and organ transplant recipients, who should avoid contact with potentially infected rodents. Overall, the prevention of LCMV relies on strict biosecurity, quarantine of new animals, and control of wild rodent populations.

In most pet rodents, LCMV infection is subclinical, and animals show no obvious signs of disease. However, when clinical signs do occur, they are often non-specific and may include weight loss, lethargy, decreased appetite, and rough hair coat. In some cases, neurological signs may be observed, including tremors, ataxia, seizures, head tilt, and paralysis. These signs are more common in mice and hamsters and may be accompanied by photophobia and hyperesthesia. In pregnant females, LCMV can cause reproductive failure, including abortion, stillbirth, and neonatal death. In hamsters, the disease can be more severe, with hepatitis, jaundice, and death. In rats, clinical signs are rare, but the virus can cause growth retardation and reduced fertility. In immunocompromised animals, the disease can be more severe and may progress to systemic illness with multi-organ involvement. It is important to note that the absence of clinical signs does not rule out infection, as persistently infected animals may shed the virus without showing any signs. Therefore, any rodent with a history of exposure to wild mice or with neurological signs should be tested for LCMV. In humans, the clinical signs of LCMV infection include fever, headache, myalgia, nausea, and vomiting, which may progress to meningitis or encephalitis. Congenital infection can cause hydrocephalus, chorioretinitis, and intellectual disability. Veterinarians should be aware of the zoonotic potential and take appropriate precautions when handling potentially infected animals.

The differential diagnoses for LCMV infection in rodents include other viral, bacterial, parasitic, and metabolic diseases that can cause similar clinical signs. Key differentials include:

1. **Sendai virus infection**: A paramyxovirus that causes respiratory disease in mice and rats, with clinical signs including dyspnea, weight loss, and ruffled fur. Diagnosis is by serology or PCR. 2. **Mouse hepatitis virus (MHV)**: A coronavirus that causes enteritis and hepatitis in mice, with clinical signs including diarrhea, jaundice, and neurological signs in some strains. Diagnosis is by PCR or serology. 3. **Rat coronavirus (RCV)**: Causes respiratory disease in rats, with clinical signs including sneezing, dyspnea, and weight loss. Diagnosis is by PCR or serology. 4. **Tyzzer's disease (Clostridium piliforme)**: A bacterial infection that causes hepatitis and enteritis in rodents, with clinical signs including diarrhea, lethargy, and death. Diagnosis is by histopathology or PCR. 5. **Bacterial meningitis**: Caused by various bacteria, including Streptococcus pneumoniae and Pasteurella multocida, can cause neurological signs in rodents. Diagnosis is by culture and sensitivity. 6. **Toxoplasmosis**: A parasitic infection caused by Toxoplasma gondii, which can cause neurological signs and reproductive failure in rodents. Diagnosis is by serology or PCR. 7. **Nutritional deficiencies**: Deficiencies of vitamin E or selenium can cause neurological signs and myopathy in rodents. Diagnosis is based on dietary history and response to supplementation. 8. **Neoplasia**: Primary or metastatic brain tumors can cause neurological signs in older rodents. Diagnosis is by imaging or histopathology. 9. **Trauma**: Head trauma can cause neurological signs in rodents, often with a history of injury. Diagnosis is based on history and physical examination. 10. **Toxicosis**: Ingestion of toxins, such as lead or organophosphates, can cause neurological signs in rodents. Diagnosis is based on history and toxicology testing.

To differentiate these conditions, a thorough diagnostic workup is necessary, including serology, PCR, bacterial culture, and histopathology.

The diagnostic approach for suspected LCMV infection in rodents should be systematic and include the following steps:

1. **Clinical triage and history**: Obtain a detailed history, including the source of the animal, exposure to wild rodents, and any clinical signs. Assess the risk of zoonotic transmission and implement appropriate biosecurity measures. 2. **Physical examination**: Perform a thorough physical examination, with attention to the neurological system, body condition, and any signs of respiratory or reproductive disease. Use species-specific restraint techniques to minimize stress. 3. **Sample collection**: Collect blood samples for serology (ELISA, IFA) and PCR. In live animals, blood can be collected from the lateral saphenous vein, jugular vein, or cranial vena cava in rats, and from the tail vein or retro-orbital sinus in mice. For PCR, whole blood or serum can be used. In deceased animals, collect tissue samples (spleen, liver, brain) for PCR and histopathology. 4. **Serology**: Perform ELISA or IFA to detect antibodies against LCMV. A positive result indicates exposure, but not necessarily active infection. Paired samples taken 2-4 weeks apart can demonstrate a rising titer. 5. **PCR**: Perform RT-PCR on blood, serum, or tissue samples to detect viral RNA. This is the most sensitive and specific test for active infection. 6. **Virus isolation**: Attempt virus isolation in cell culture (e.g., Vero cells) from blood or tissue samples. This is the gold standard but is time-consuming and requires specialized facilities. 7. **Histopathology**: If necropsy is performed, collect tissues for histopathology. Characteristic findings include lymphocytic infiltration of the meninges and choroid plexus, and perivascular cuffing in the brain. 8. **Differential diagnosis**: Rule out other causes of neurological and systemic disease through appropriate testing, such as bacterial culture, PCR for other viruses, and toxicology. 9. **Zoonotic risk assessment**: Inform the owner of the zoonotic potential and recommend testing for any exposed humans, especially pregnant women or immunocompromised individuals.

This algorithm ensures a comprehensive and safe diagnostic approach.

Laboratory findings in LCMV-infected rodents are often non-specific, but they can support the diagnosis. Hematology may reveal leukopenia or lymphopenia in the acute phase, followed by lymphocytosis during recovery. In severe cases, there may be anemia and thrombocytopenia. Serum biochemistry may show elevated liver enzymes (ALT, AST) and bilirubin in cases with hepatitis, particularly in hamsters. In cases with neurological involvement, cerebrospinal fluid (CSF) analysis may reveal lymphocytic pleocytosis and elevated protein. However, CSF collection is rarely performed in live rodents due to the risk of complications. Serology is the most common diagnostic test, with ELISA and IFA being used to detect IgG and IgM antibodies. A four-fold rise in antibody titer between acute and convalescent samples is diagnostic. PCR is highly sensitive and specific for detecting viral RNA in blood, serum, or tissues. It is particularly useful in persistently infected animals that may have low antibody titers. Virus isolation can be performed from blood, urine, or tissue homogenates, but it requires biosafety level 3 facilities. Histopathology of the brain, liver, and spleen may show lymphocytic infiltration, necrosis, and inclusion bodies. In persistently infected mice, the virus can be detected in the blood and organs by immunohistochemistry or in situ hybridization. Overall, the diagnosis of LCMV relies on a combination of serology, PCR, and histopathology.

Imaging studies are not commonly used in the diagnosis of LCMV in rodents, but they may be helpful in evaluating neurological signs. Radiography can be used to assess the skull for fractures or other abnormalities, but it is not sensitive for detecting brain lesions. Ultrasonography may be used to evaluate abdominal organs, such as the liver and spleen, for evidence of hepatomegaly or splenomegaly. Computed tomography (CT) and magnetic resonance imaging (MRI) are the most sensitive imaging modalities for evaluating the brain and spinal cord. In cases of LCMV encephalitis, MRI may show hyperintense lesions in the meninges and brain parenchyma on T2-weighted images. However, these imaging modalities are rarely available in exotic animal practice and are not routinely recommended. In cases of reproductive failure, ultrasonography may be used to assess the uterus and fetuses. Overall, imaging is of limited diagnostic value in LCMV infection, and the diagnosis is primarily based on serology and PCR.

Cytology and histopathology can provide valuable diagnostic information in cases of LCMV infection. Fine-needle aspiration of enlarged lymph nodes or spleen may reveal lymphocytic proliferation. Cerebrospinal fluid analysis, if performed, may show lymphocytic pleocytosis. Histopathology of the brain is the most definitive diagnostic tool, with characteristic findings including lymphocytic infiltration of the meninges and choroid plexus, perivascular cuffing, and gliosis. In the liver, there may be focal necrosis and lymphocytic infiltration. In the spleen, there may be lymphoid hyperplasia. In persistently infected mice, the virus can be detected in tissues by immunohistochemistry, which shows viral antigen in the meninges, ependyma, and hepatocytes. In congenital infections, the brain may show hydrocephalus and chorioretinitis. Histopathology is also useful for ruling out other causes of neurological disease, such as bacterial meningitis or neoplasia. It is important to collect tissues from multiple organs, including the brain, liver, spleen, and lungs, for a comprehensive evaluation.

There is no specific antiviral treatment for LCMV infection in rodents. Treatment is primarily supportive and focuses on managing clinical signs and preventing secondary infections. In cases with neurological signs, supportive care may include fluid therapy, nutritional support, and anticonvulsants if seizures are present. Fluid therapy can be administered subcutaneously or intravenously, with isotonic crystalloids such as lactated Ringer's solution at a rate of 50-100 ml/kg/day. Nutritional support may be provided via syringe feeding with a critical care formula for herbivores or omnivores. In cases with secondary bacterial infections, appropriate antibiotics should be administered based on culture and sensitivity. However, antibiotics are not effective against the virus itself. Corticosteroids are contraindicated because they can exacerbate the infection by suppressing the immune response. In persistently infected animals, treatment is not recommended because they will continue to shed the virus and pose a zoonotic risk. Euthanasia may be considered for animals with severe neurological disease or for those that are persistently infected and pose a public health risk. Prevention is the most important aspect of management, including strict biosecurity, quarantine of new animals, and control of wild rodents. Owners should be educated about the zoonotic potential and the importance of hand hygiene and personal protective equipment when handling potentially infected animals.

The prognosis for LCMV infection in rodents is generally good for immunocompetent adult animals, as the infection is often self-limiting and clinical signs are mild or absent. Most animals recover within 2-3 weeks without specific treatment. However, the prognosis is guarded for neonates, immunocompromised animals, and those with severe neurological signs. In hamsters, the disease can be more severe and may result in death. Persistently infected animals have a poor prognosis for recovery and are a chronic source of viral shedding. The prognosis for the colony is also poor if the virus becomes enzootic, as it is difficult to eliminate. In terms of zoonotic risk, the prognosis for humans is generally good, with most cases being self-limiting, but congenital infection can cause severe fetal damage. Therefore, the prognosis for the affected rodent must be weighed against the public health risk, and euthanasia may be recommended in certain situations.

Follow-up for LCMV-infected rodents should include serial monitoring of clinical signs and viral shedding. In animals that recover from acute infection, the virus is typically cleared within 2-3 weeks, and no further treatment is needed. However, it is important to monitor for any long-term sequelae, such as neurological deficits. In persistently infected animals, follow-up is not recommended because they will continue to shed the virus and pose a zoonotic risk. In a colony setting, serological monitoring should be performed on a regular basis to detect new infections. Quarantine of new animals for at least 4-6 weeks and testing for LCMV before introduction is essential. Owners should be advised to practice good hygiene and to avoid contact with potentially infected rodents, especially if they are pregnant or immunocompromised. If a human exposure occurs, the individual should seek medical attention and inform their healthcare provider about the potential LCMV exposure. Overall, follow-up should focus on prevention and biosecurity.

**Pearls:** - Always consider LCMV in the differential diagnosis of any rodent with neurological signs, especially if there is a history of exposure to wild mice. - Use appropriate personal protective equipment (gloves, mask, eye protection) when handling potentially infected rodents to prevent zoonotic transmission. - Educate owners about the zoonotic risk, especially for pregnant women and immunocompromised individuals. - Implement strict biosecurity measures, including quarantine of new animals and control of wild rodents, to prevent introduction of the virus into a colony. - Use PCR for diagnosis in live animals, as it is highly sensitive and specific.

**Pitfalls:** - Do not use corticosteroids in LCMV-infected animals, as they can exacerbate the infection. - Do not assume that a negative serology result rules out infection, as persistently infected animals may have low antibody titers. - Do not overlook the zoonotic risk; always inform the owner and recommend testing for exposed humans. - Do not attempt to treat persistently infected animals, as they will continue to shed the virus and pose a public health risk. - Do not forget to disinfect the environment with appropriate disinfectants, such as 10% bleach, to prevent spread to other animals and humans.

There is no specific antiviral therapy for LCMV in rodents. Treatment is supportive and symptomatic. The following drug protocols may be used based on clinical signs and species-specific considerations:

- **Fluid therapy**: Lactated Ringer's solution or Normosol-R, 50-100 ml/kg/day SC or IV. For rats and mice, the subcutaneous route is preferred; for hamsters, the intraperitoneal route may be used. - **Nutritional support**: Critical Care for Herbivores (Oxbow) or Emeraid Omnivore, 10-20 ml/kg PO q6-8h via syringe feeding. - **Anticonvulsants**: Diazepam, 0.5-2 mg/kg IM or IV as needed for seizures. For rats and mice, diazepam can be administered at 1-2 mg/kg IM; for hamsters, 0.5-1 mg/kg IM. - **Antibiotics**: If secondary bacterial infection is suspected, use appropriate antibiotics based on culture and sensitivity. Common choices include: - Enrofloxacin, 10 mg/kg PO q12h for rats and mice; 10 mg/kg PO q12h for hamsters. - Trimethoprim-sulfamethoxazole, 30 mg/kg PO q12h for rats and mice; 30 mg/kg PO q12h for hamsters. - **Analgesics**: If pain is present, use buprenorphine, 0.01-0.05 mg/kg SC or IM q8-12h for rats and mice; 0.01-0.05 mg/kg SC or IM q8-12h for hamsters.

Note: These dosages are based on Carpenter's Exotic Animal Formulary and should be adjusted based on the individual animal's condition and response to therapy. Always consult a veterinarian experienced in exotic animal medicine before administering any medication.

The literature on LCMV in exotic pet rodents is limited, but there are several key studies and reviews that provide evidence-based guidance. A landmark study by Childs et al. (1992) investigated the prevalence of LCMV in wild house mice in the United States and found a seroprevalence of 5-20%, highlighting the potential for zoonotic transmission. Another study by Amman et al. (2007) reported an outbreak of LCMV in a hamster colony in the United States, which resulted in human infections, emphasizing the importance of biosecurity in pet rodent breeding facilities. In terms of diagnosis, a study by Ledesma et al. (2009) evaluated the use of RT-PCR for the detection of LCMV in rodents and found it to be highly sensitive and specific. A review by Bonthius (2012) summarized the pathogenesis of LCMV infection in mice and humans, providing insights into the immune-mediated mechanisms of disease. In the field of exotic animal medicine, the BSAVA Manual of Exotic Pets and Quesenberry and Carpenter's Ferrets, Rabbits, and Rodents provide practical guidelines for the diagnosis and management of LCMV in pet rodents. The consensus among experts is that prevention is the most important strategy, and that testing and quarantine of new animals are essential to prevent the introduction of LCMV into pet rodent populations. Additionally, the zoonotic risk should be communicated to owners, and appropriate precautions should be taken to protect human health.